Cellestia Biotech

Cellestia Biotech is a clinical-stage biopharmaceutical company developing first-in-class therapeutics targeting the Notch signaling pathway for the treatment of multi-drug resistant cancers and autoimmune diseases. Its lead candidate CB-103, an oral pan-Notch inhibitor, has demonstrated safety and biological activity in Phase 1 trials and is advancing into Phase 2 for hematologic and solid tumor cancers, as well as proof-of-concept studies in graft-versus-host disease. Founded on pioneering academic research, Cellestia addresses cancers where conventional therapies fail by exploiting a novel mode of transcriptional inhibition distinct from prior Notch-targeting approaches.